Lavo Life Sciences

Crystal form surprises can sink a drug late in development. Lavo Life Sciences is an AI research tool that predicts the crystal structures of small molecule drugs, so teams can spot solid-state problems earlier.

The company is a VC-backed, early-stage startup building software for drug development, and its focus is narrow: how a small molecule packs into a crystal.

The product is a web-based platform called Crystal Console.

Inside it you get tools for crystal structure analysis, virtual polymorph screening and PXRD analysis.

Virtual polymorph screening means Lavo can look at possible crystal forms computationally, before a lab has to find them the hard way.

Lavo says this helps de-risk pipelines, optimize solid-state formulations and avoid late-stage surprises.

That makes Lavo Life Sciences most relevant to pharmaceutical and biotech groups working with small molecules, particularly formulation and solid-state scientists.

It is not a general data analysis product, and it will not help with biologics or broad healthcare analytics.

Because the company is early-stage, expect a young product rather than a long-established platform.